Cargando…
Agonist Effects of Propranolol on Non-Tumor Human Breast Cells
The β-blocker propranolol (PROP) has been proposed as a repurposed treatment for breast cancer. The similarity of action between β-agonists and antagonists found on breast cells encouraged us to compare PROP and isoproterenol (ISO, agonist) signaling pathways on a human breast cell line. Cell prolif...
Autores principales: | Gargiulo, Lucía, Rivero, Ezequiel Mariano, di Siervi, Nicolás, Buzzi, Edgardo David, Buffone, Mariano Gabriel, Davio, Carlos Alberto, Lüthy, Isabel Alicia, Bruzzone, Ariana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226086/ https://www.ncbi.nlm.nih.gov/pubmed/32331276 http://dx.doi.org/10.3390/cells9041036 |
Ejemplares similares
-
Differential β(2)-adrenergic receptor expression defines the phenotype of non-tumorigenic and malignant human breast cell lines
por: Gargiulo, Lucía, et al.
Publicado: (2014) -
Multidrug resistance protein 4/ ATP binding cassette transporter 4: a new potential therapeutic target for acute myeloid leukemia
por: Copsel, Sabrina, et al.
Publicado: (2014) -
Successful treatment of eruptive pyogenic granuloma with propranolol
por: Fattore, Davide, et al.
Publicado: (2021) -
Inhibition of Endothelin system during the postnatal nephrogenic period in the rat. Its relationship with hypertension and renal disease in adulthood
por: Albertoni Borghese, María Florencia, et al.
Publicado: (2020) -
Role of propranolol in hemangiomas
por: Gajbhiye, Vishal, et al.
Publicado: (2011)